Use of FK 506 in pancreas transplantation

Rainer W G Gruessner, David E R Sutherland, Mary Beth Drangstveit, Christoph Troppmann, Angelika C. Gruessner

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Until recently, FK 506 was used only for rescue therapy after pancreas transplantation. We report our initial experience with FK 506 for 67 pancreas recipients (treated between 1 May 1993 and 30 April 1995). Of these recipients, 49 (73%) received FK 506 for induction and maintenance therapy, 12 (18%) for rescue or antirejection therapy, and 6 (9%) for reasons other than rescue or antirejection therapy. In our induction and maintenance therapy group, 32 recipients (65%) underwent a simultaneous pancreas-kidney transplant (SPK), 8 (16%) a pancreas transplant alone (PTA), and 9 (19%) a pancreas after previous kidney transplant (PAK). Quadruple immunosuppression was used for induction; the median FK 506 starting dose was 4 mg/day p.o. and target levels were 10-20 ng/ml. The most common side effects were nephrotoxicity (16%) and neurotoxicity (14%); transient episodes of hyperglycemia were also noted (12%), in particular in the presence of concurrent rejection and infection episodes. A matched-pair analysis was done to compare graft outcome with FK 506 versus cyclosporin A (CsA). For SPK recipients, pancreas graft survival at 6 months was 79% with FK 506 versus 65% with CsA (P = 0.04), for PTA, 100% versus 63% (P > 0.35), and for PAK, 88% versus 33% (P > 0.01). Pancreas graft loss due to rejection at 6 months posttransplant was lower with FK 506 versus CsA. Two FK 506 recipients died from B-cell lymphomas (Epstein-Barr virus positive) at 6 and 7 months posttransplant. In our rescue or antirejection group, 5 recipients underwent SPK, 3 PTA, and 4 PAK. The mean average FK 506 dose was 10 mg/day p.o. and the mean average FK 506 blood level was 11 ng/ml. The most common side effects were nephrotoxicity (33%) and neurotoxicity (16%). Two recipients developed hyperglycemic episodes, of whom 1 has remained on insulin with good exocrine pancreas graft function. Graft survival at 6 months after conversion was 75% for SPK, 67% for PTA, and 50% for PAK. Only one graft was lost due to chronic rejection. Our single-center experience shows that FK 506 after pancreas transplantation is associated with: (1) a low rate of graft loss due to rejection when used for induction, in particular for solitary pancreas transplants, (2) a high rate of graft salvage when used for rescue, (3) a 1% rate of new-onset insulin-dependent diabetes mellitus, and (4) a 3% rate of posttransplant lymphoma. Further studies are necessary to analyze the long-term impact of FK 506 on pancreas transplant outcome.

Original languageEnglish (US)
JournalTransplant International
Volume9
Issue numberSUPPL. 1
StatePublished - 1996
Externally publishedYes

Fingerprint

Pancreas Transplantation
Tacrolimus
Pancreas
Transplants
Kidney
Immunosuppression
Cyclosporine
Graft Survival
Matched-Pair Analysis
Exocrine Pancreas
B-Cell Lymphoma
Group Psychotherapy

Keywords

  • FK 506
  • Pancreas transplantation
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation

Cite this

Gruessner, R. W. G., Sutherland, D. E. R., Drangstveit, M. B., Troppmann, C., & Gruessner, A. C. (1996). Use of FK 506 in pancreas transplantation. Transplant International, 9(SUPPL. 1).

Use of FK 506 in pancreas transplantation. / Gruessner, Rainer W G; Sutherland, David E R; Drangstveit, Mary Beth; Troppmann, Christoph; Gruessner, Angelika C.

In: Transplant International, Vol. 9, No. SUPPL. 1, 1996.

Research output: Contribution to journalArticle

Gruessner, RWG, Sutherland, DER, Drangstveit, MB, Troppmann, C & Gruessner, AC 1996, 'Use of FK 506 in pancreas transplantation', Transplant International, vol. 9, no. SUPPL. 1.
Gruessner RWG, Sutherland DER, Drangstveit MB, Troppmann C, Gruessner AC. Use of FK 506 in pancreas transplantation. Transplant International. 1996;9(SUPPL. 1).
Gruessner, Rainer W G ; Sutherland, David E R ; Drangstveit, Mary Beth ; Troppmann, Christoph ; Gruessner, Angelika C. / Use of FK 506 in pancreas transplantation. In: Transplant International. 1996 ; Vol. 9, No. SUPPL. 1.
@article{ab49c246b162431e809317a07efd65a0,
title = "Use of FK 506 in pancreas transplantation",
abstract = "Until recently, FK 506 was used only for rescue therapy after pancreas transplantation. We report our initial experience with FK 506 for 67 pancreas recipients (treated between 1 May 1993 and 30 April 1995). Of these recipients, 49 (73{\%}) received FK 506 for induction and maintenance therapy, 12 (18{\%}) for rescue or antirejection therapy, and 6 (9{\%}) for reasons other than rescue or antirejection therapy. In our induction and maintenance therapy group, 32 recipients (65{\%}) underwent a simultaneous pancreas-kidney transplant (SPK), 8 (16{\%}) a pancreas transplant alone (PTA), and 9 (19{\%}) a pancreas after previous kidney transplant (PAK). Quadruple immunosuppression was used for induction; the median FK 506 starting dose was 4 mg/day p.o. and target levels were 10-20 ng/ml. The most common side effects were nephrotoxicity (16{\%}) and neurotoxicity (14{\%}); transient episodes of hyperglycemia were also noted (12{\%}), in particular in the presence of concurrent rejection and infection episodes. A matched-pair analysis was done to compare graft outcome with FK 506 versus cyclosporin A (CsA). For SPK recipients, pancreas graft survival at 6 months was 79{\%} with FK 506 versus 65{\%} with CsA (P = 0.04), for PTA, 100{\%} versus 63{\%} (P > 0.35), and for PAK, 88{\%} versus 33{\%} (P > 0.01). Pancreas graft loss due to rejection at 6 months posttransplant was lower with FK 506 versus CsA. Two FK 506 recipients died from B-cell lymphomas (Epstein-Barr virus positive) at 6 and 7 months posttransplant. In our rescue or antirejection group, 5 recipients underwent SPK, 3 PTA, and 4 PAK. The mean average FK 506 dose was 10 mg/day p.o. and the mean average FK 506 blood level was 11 ng/ml. The most common side effects were nephrotoxicity (33{\%}) and neurotoxicity (16{\%}). Two recipients developed hyperglycemic episodes, of whom 1 has remained on insulin with good exocrine pancreas graft function. Graft survival at 6 months after conversion was 75{\%} for SPK, 67{\%} for PTA, and 50{\%} for PAK. Only one graft was lost due to chronic rejection. Our single-center experience shows that FK 506 after pancreas transplantation is associated with: (1) a low rate of graft loss due to rejection when used for induction, in particular for solitary pancreas transplants, (2) a high rate of graft salvage when used for rescue, (3) a 1{\%} rate of new-onset insulin-dependent diabetes mellitus, and (4) a 3{\%} rate of posttransplant lymphoma. Further studies are necessary to analyze the long-term impact of FK 506 on pancreas transplant outcome.",
keywords = "FK 506, Pancreas transplantation, Tacrolimus",
author = "Gruessner, {Rainer W G} and Sutherland, {David E R} and Drangstveit, {Mary Beth} and Christoph Troppmann and Gruessner, {Angelika C.}",
year = "1996",
language = "English (US)",
volume = "9",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Use of FK 506 in pancreas transplantation

AU - Gruessner, Rainer W G

AU - Sutherland, David E R

AU - Drangstveit, Mary Beth

AU - Troppmann, Christoph

AU - Gruessner, Angelika C.

PY - 1996

Y1 - 1996

N2 - Until recently, FK 506 was used only for rescue therapy after pancreas transplantation. We report our initial experience with FK 506 for 67 pancreas recipients (treated between 1 May 1993 and 30 April 1995). Of these recipients, 49 (73%) received FK 506 for induction and maintenance therapy, 12 (18%) for rescue or antirejection therapy, and 6 (9%) for reasons other than rescue or antirejection therapy. In our induction and maintenance therapy group, 32 recipients (65%) underwent a simultaneous pancreas-kidney transplant (SPK), 8 (16%) a pancreas transplant alone (PTA), and 9 (19%) a pancreas after previous kidney transplant (PAK). Quadruple immunosuppression was used for induction; the median FK 506 starting dose was 4 mg/day p.o. and target levels were 10-20 ng/ml. The most common side effects were nephrotoxicity (16%) and neurotoxicity (14%); transient episodes of hyperglycemia were also noted (12%), in particular in the presence of concurrent rejection and infection episodes. A matched-pair analysis was done to compare graft outcome with FK 506 versus cyclosporin A (CsA). For SPK recipients, pancreas graft survival at 6 months was 79% with FK 506 versus 65% with CsA (P = 0.04), for PTA, 100% versus 63% (P > 0.35), and for PAK, 88% versus 33% (P > 0.01). Pancreas graft loss due to rejection at 6 months posttransplant was lower with FK 506 versus CsA. Two FK 506 recipients died from B-cell lymphomas (Epstein-Barr virus positive) at 6 and 7 months posttransplant. In our rescue or antirejection group, 5 recipients underwent SPK, 3 PTA, and 4 PAK. The mean average FK 506 dose was 10 mg/day p.o. and the mean average FK 506 blood level was 11 ng/ml. The most common side effects were nephrotoxicity (33%) and neurotoxicity (16%). Two recipients developed hyperglycemic episodes, of whom 1 has remained on insulin with good exocrine pancreas graft function. Graft survival at 6 months after conversion was 75% for SPK, 67% for PTA, and 50% for PAK. Only one graft was lost due to chronic rejection. Our single-center experience shows that FK 506 after pancreas transplantation is associated with: (1) a low rate of graft loss due to rejection when used for induction, in particular for solitary pancreas transplants, (2) a high rate of graft salvage when used for rescue, (3) a 1% rate of new-onset insulin-dependent diabetes mellitus, and (4) a 3% rate of posttransplant lymphoma. Further studies are necessary to analyze the long-term impact of FK 506 on pancreas transplant outcome.

AB - Until recently, FK 506 was used only for rescue therapy after pancreas transplantation. We report our initial experience with FK 506 for 67 pancreas recipients (treated between 1 May 1993 and 30 April 1995). Of these recipients, 49 (73%) received FK 506 for induction and maintenance therapy, 12 (18%) for rescue or antirejection therapy, and 6 (9%) for reasons other than rescue or antirejection therapy. In our induction and maintenance therapy group, 32 recipients (65%) underwent a simultaneous pancreas-kidney transplant (SPK), 8 (16%) a pancreas transplant alone (PTA), and 9 (19%) a pancreas after previous kidney transplant (PAK). Quadruple immunosuppression was used for induction; the median FK 506 starting dose was 4 mg/day p.o. and target levels were 10-20 ng/ml. The most common side effects were nephrotoxicity (16%) and neurotoxicity (14%); transient episodes of hyperglycemia were also noted (12%), in particular in the presence of concurrent rejection and infection episodes. A matched-pair analysis was done to compare graft outcome with FK 506 versus cyclosporin A (CsA). For SPK recipients, pancreas graft survival at 6 months was 79% with FK 506 versus 65% with CsA (P = 0.04), for PTA, 100% versus 63% (P > 0.35), and for PAK, 88% versus 33% (P > 0.01). Pancreas graft loss due to rejection at 6 months posttransplant was lower with FK 506 versus CsA. Two FK 506 recipients died from B-cell lymphomas (Epstein-Barr virus positive) at 6 and 7 months posttransplant. In our rescue or antirejection group, 5 recipients underwent SPK, 3 PTA, and 4 PAK. The mean average FK 506 dose was 10 mg/day p.o. and the mean average FK 506 blood level was 11 ng/ml. The most common side effects were nephrotoxicity (33%) and neurotoxicity (16%). Two recipients developed hyperglycemic episodes, of whom 1 has remained on insulin with good exocrine pancreas graft function. Graft survival at 6 months after conversion was 75% for SPK, 67% for PTA, and 50% for PAK. Only one graft was lost due to chronic rejection. Our single-center experience shows that FK 506 after pancreas transplantation is associated with: (1) a low rate of graft loss due to rejection when used for induction, in particular for solitary pancreas transplants, (2) a high rate of graft salvage when used for rescue, (3) a 1% rate of new-onset insulin-dependent diabetes mellitus, and (4) a 3% rate of posttransplant lymphoma. Further studies are necessary to analyze the long-term impact of FK 506 on pancreas transplant outcome.

KW - FK 506

KW - Pancreas transplantation

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=0029853732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029853732&partnerID=8YFLogxK

M3 - Article

VL - 9

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - SUPPL. 1

ER -